🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalSingapore HSA regulations — 12 month update Page 5

Singapore HSA regulations — 12 month update

quinn_sf Wed, Sep 11, 2024 at 1:49 PM 36 replies 2,367 viewsPage 5 of 8
RickReta_CO
Member
312
1,234
Jan 2025
Colorado
Sep 23, 2024 at 4:10 AM#21
JessicaM_2024 said:
Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

Can confirm. Same sequence, different timescale. Nothing to add that would improve it.

50 0matt_MKE, Dr.ReproEndo, lucas_SP_BR and 47 others
Reply Quote Save Share Report
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Sep 27, 2024 at 10:58 AM#22
JessicaM_2024 said:
Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.

There is a second half to this that has not been said yet. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Last edited: Sep 27, 2024 at 11:58 AM
49 24jim_asheville, matt_MKE, Dr.ReproEndo and 46 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Oct 1, 2024 at 5:49 PM#23

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Last edited: Oct 1, 2024 at 8:49 PM
48 23MikeNYC_runner and 45 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Oct 6, 2024 at 12:42 AM#24

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Oct 6, 2024 at 2:42 AM
47 22TomFromTexas, mike.trainer_LA, sarah_nash92 and 44 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Oct 10, 2024 at 7:38 AM#25
FDA_TrackerJim said:
Practical: whatever you change, write down the date and the reason.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

46 21Dr.LipidDallas, alex_tucson, kevin_tulsa and 43 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register